Summary: Ariceum Therapeutics has signed an agreement with NorthStar Medical Radioisotopes to obtain high-purity Actinium-225 for developing satoreotide, a theranostic agent for diagnosing and treating cancers such as small cell lung cancer, pancreatic cancer, and Merkel cell carcinoma.

Key Takeaways

  • Supply Agreement for Ac-225: Ariceum Therapeutics has secured a supply agreement with NorthStar Medical Radioisotopes for high-purity Actinium-225 to support its clinical programs.
  • Development of Satoreotide: Ariceum will use Ac-225 to radiolabel satoreotide (SS0110), an SSTR2 antagonist in development as a theranostic agent for diagnosing and treating cancers like small cell lung cancer, pancreatic cancer, and Merkel cell carcinoma.
  • First Ac-225-Labeled SSTR2 Antagonist: Satoreotide is the first Ac-225-labeled SSTR2 antagonist targeting small cell lung cancer and is set to enter clinical development in the U.S.

———————————————————————————————————————————————————

Ariceum Therapeutics, a biotech company focused on radiopharmaceuticals for diagnosing and treating hard-to-treat cancers, has signed a supply agreement with NorthStar Medical Radioisotopes for the therapeutic radioisotope Actinium-225 (Ac-225).

Under the agreement, NorthStar will supply Ariceum with non-carrier-added, high-purity Ac-225 to support its clinical programs. Ariceum will use Ac-225 to radiolabel satoreotide (SS0110), a somatostatin receptor 2 (SSTR2) antagonist in development as a theranostic agent for diagnosing and treating cancers such as small cell lung cancer (SCLC), pancreatic cancer, and Merkel cell carcinoma.

“Satoreotide is the first Ac-225-labeled SSTR2 antagonist targeting SCLC and will soon enter clinical development in the U.S,” says Manfred Rüdiger, CEO of Ariceum. “Its Lutetium-177-labeled version has shown promise in ongoing trials. NorthStar’s expertise in radioisotope production makes them a reliable partner for advancing our studies and future commercialization.”

NorthStar’s CEO Frank Scholz also spoke out about the agreement, stating: “We are committed to ensuring reliable Ac-225 availability to support clinical trials and patient treatments, enabling innovative therapies for aggressive cancers with limited options. By addressing the global shortage of Ac-225, we aim to accelerate the development of groundbreaking radiopharmaceuticals and contribute to improved treatment outcomes for patients facing some of the most challenging diagnoses.”